107 related articles for article (PubMed ID: 26472564)
1. Safe dose reduction of steroid pre-medication for docetaxel in head and neck neoplasm treatment.
Chen NX; Zhao FF; Yan F; Zhang XX
Acta Otolaryngol; 2016; 136(2):177-80. PubMed ID: 26472564
[TBL] [Abstract][Full Text] [Related]
2. Single premedication dose of dexamethasone 20 mg IV before docetaxel administration.
Chouhan JD; Herrington JD
J Oncol Pharm Pract; 2011 Sep; 17(3):155-9. PubMed ID: 20447949
[TBL] [Abstract][Full Text] [Related]
3. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
Köppler H; Heymanns J; Weide R
Onkologie; 2001 Jun; 24(3):283-5. PubMed ID: 11455223
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?
Schwartz JR
J Oncol Pharm Pract; 2012 Jun; 18(2):250-6. PubMed ID: 21807762
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel.
Kang RY; Yoo KS; Han HJ; Lee JY; Lee SH; Kim DW; Lee YJ
Support Care Cancer; 2017 Feb; 25(2):429-437. PubMed ID: 27687722
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel pre-medication: A comparison of two steroid pre-medication protocols.
Yenilmez A; Hood AP; Nguyen LH; Merl MY
J Oncol Pharm Pract; 2017 Oct; 23(7):491-495. PubMed ID: 27530242
[TBL] [Abstract][Full Text] [Related]
7. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
8. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
Parinyanitikul N; Tanpipattanakul W; Poovorawan N; Rattananupong T; Laoitthi P; Sithidetphaiboon P; Thanasanvimon S; Sriuranpong V
Support Care Cancer; 2018 Jul; 26(7):2471-2477. PubMed ID: 29435713
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment with different doses of dexamethasone in the prevention of docetaxel-induced hypersensitivity.
Zhang M; Chen Z; Yang Y; Cheng H; Li C; He Q
Pak J Pharm Sci; 2017 Jan; 30(1):61-65. PubMed ID: 28603114
[TBL] [Abstract][Full Text] [Related]
10. Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients.
Jacobs C; Hutton B; Mazzarello S; Smith S; Joy A; Amir E; Ibrahim MF; Gregario N; Daigle K; Eggert L; Clemons M
Support Care Cancer; 2015 Nov; 23(11):3269-75. PubMed ID: 25933700
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
13. A randomized clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy.
Hsu T; Fergusson D; Stober C; Daigle K; Moledina N; Vandermeer L; Pond G; Hilton J; Hutton B; Clemons M;
Support Care Cancer; 2021 Jun; 29(6):3113-3120. PubMed ID: 33057999
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
16. A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
Hosonaga M; Ito Y; Tokudome N; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2012 Oct; 19(4):329-34. PubMed ID: 21863309
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
[TBL] [Abstract][Full Text] [Related]
18. Cross-sensitivity between taxanes in patients with breast cancer.
Sánchez-Muñoz A; Jiménez B; García-Tapiador A; Romero-García G; Medina L; Navarro V; González-Sánchez LA; Alba E
Clin Transl Oncol; 2011 Dec; 13(12):904-6. PubMed ID: 22126735
[TBL] [Abstract][Full Text] [Related]
19. Successful desensitization to docetaxel after severe hypersensitivity reactions in two patients.
Reeves DJ; Callahan MJ; Sutton GP
Am J Health Syst Pharm; 2012 Mar; 69(6):499-503. PubMed ID: 22382481
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Haddad RI; Tishler RB; Norris C; Goguen L; Balboni TA; Costello R; Wirth L; Lorch J; Andreozzi B; Annino D; Posner MR
J Clin Oncol; 2009 Sep; 27(27):4448-53. PubMed ID: 19704061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
